Analysis of 24 studies revealed that mutations in kras, idh1/2, and tp53 significantly affect long-term survival outcomes in patients with resectable intrahepatic cholangiocarcinoma. Specifically, kras mutations increased the risk (HR: 2.476), while idh1/2 mutations suggested a protective effect (HR: 0.624). tp53 mutations also indicated a higher risk (HR: 2.771). Notably, the prevalence of kras and idh1/2 mutations varied significantly between Western and Eastern populations, highlighting geographical disparities in genetic factors.
Systematic Review by Giannone F, Del Zompo F (…) Pessaux P et 4 al. in Br J Surg
© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.